Overview
At a Glance
Renuva is an allograft adipose matrix (AAM) manufactured by MTF Biologics. Unlike synthetic dermal fillers or biostimulators, Renuva is processed from donated human adipose (fat) tissue. The donated fat is decellularized — stripped of living cells and lipids — leaving behind the extracellular matrix scaffold that naturally supports fat tissue. When injected, this scaffold recruits the patient's own stem cells and adipocytes, promoting neoadipogenesis: the body generates new fat cells within the matrix, effectively replacing the injected material with the patient's own living tissue. Renuva is FDA-regulated as a human tissue product (HCT/P) under 21 CFR Part 1271 and is used in aesthetic medicine for volume restoration in the face, hands, feet, and body.Adipose tissue loss is a hallmark of aging and a consequence of trauma, surgery, and medical treatments such as radiation therapy. Historically, volume restoration in these contexts has been addressed through two primary approaches: synthetic injectable fillers (hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid) and autologous fat transfer, in which a patient's own fat is harvested via liposuction and reinjected elsewhere.
Both approaches carry limitations. Synthetic fillers are temporary — they degrade over 6–24 months and require repeat treatments. Autologous fat transfer requires a surgical harvest procedure with donor site morbidity, operative time, and unpredictable graft survival rates ranging from 20% to 80% depending on technique and location (Gold et al., 2020).
Renuva was developed to bridge this gap: an off-the-shelf, injectable tissue product that provides the biological benefits of fat grafting — native tissue integration, adipogenesis, long-term volume — without requiring a surgical harvest from the patient. The product is aseptically processed from donated human adipose tissue without terminal irradiation, preserving the structural and biochemical properties of the extracellular matrix (Gold et al., 2024).
Quick Facts
| Property | Details |
|---|---|
| Material | Decellularized human allograft adipose tissue (extracellular matrix) |
| Source | Donated human tissue, screened per FDA and AATB standards |
| Processing | Aseptic decellularization; no terminal irradiation |
| Immunogenicity | Nonimmunogenic (cellular components removed) |
| Mechanism | Scaffold-mediated neoadipogenesis and neovascularization |
| FDA regulation | Human tissue product (HCT/P) under 21 CFR Part 1271, Section 361 |
| Allergy testing | Not required (human-derived, acellular) |
| Storage | Room temperature; 5-year shelf life |
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
Decellularization and Processing
Renuva begins as donated human adipose tissue recovered from consented tissue donors. MTF Biologics processes the tissue through a proprietary decellularization protocol that removes all living cells, lipids, and blood components while preserving the three-dimensional architecture of the extracellular matrix (ECM). The result is an acellular, off-white injectable matrix that retains:
- Structural proteins: Collagens (types I, IV, VI), laminin, fibronectin — the scaffolding that defines fat tissue architecture
- Glycosaminoglycans: Including hyaluronic acid and proteoglycans that support hydration and cell signaling
- Growth factors: Residual adipogenic and angiogenic growth factors embedded in the matrix
- Native tissue geometry: The three-dimensional pore structure and mechanical properties that guide cell behavior
The processing is performed aseptically without terminal irradiation, which would denature the matrix proteins and compromise biological activity. Donor tissue is screened according to FDA requirements and American Association of Tissue Banks (AATB) standards (Gold et al., 2024).
Mechanism of Action: Scaffold-Mediated Adipogenesis
After injection, the Renuva matrix initiates a biological cascade fundamentally different from synthetic fillers:
- Scaffold integration (days 1–7): The injected matrix integrates with surrounding tissue. Host inflammatory cells arrive and begin processing the scaffold — this is a normal, constructive remodeling response, not a foreign body reaction.
- Cell recruitment (weeks 1–4): The matrix's retained growth factors and structural cues recruit adipose-derived stem cells (ADSCs), preadipocytes, and endothelial progenitor cells from surrounding tissue. These cells migrate into the scaffold's pore structure.
- Neovascularization (weeks 2–8): New blood vessels form throughout the matrix, establishing the vascular supply necessary to sustain developing fat tissue. Histological studies of Renuva-treated tissue have confirmed robust angiogenesis within the scaffold (Gold et al., 2020).
- Adipogenesis (weeks 4–24): Recruited stem cells differentiate into mature, lipid-laden adipocytes within the scaffold. The matrix is progressively remodeled and replaced by the patient's own living fat tissue.
- Tissue maturation (months 3–6+): The remodeled tissue matures into stable, vascularized fat with native architecture. Biopsy specimens from clinical studies have confirmed the presence of mature adipocytes and functional blood vessels within treated sites (Gold et al., 2020).
Key Distinction: Regeneration vs. Filling
This mechanism represents a fundamentally different approach from traditional dermal fillers. Hyaluronic acid fillers physically occupy space with a synthetic gel that is gradually degraded by the body. Biostimulators like Sculptra trigger collagen production around an injected particle. Renuva, by contrast, provides a biological template for the body to regenerate its own fat tissue in the treated area — the end result is native adipose tissue, not a foreign material.
This distinction has practical implications: the volume created by Renuva is living tissue that responds to physiological changes (weight gain/loss, aging) as any other fat depot would. The initial volume after injection may decrease as the matrix is remodeled, then increase as new adipocytes mature and accumulate lipid — producing a characteristic "dip and recovery" pattern in volume measurements over the first 12–24 weeks (Gold et al., 2020).
Go Deeper
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Clinical Evidence
Multicenter Pilot Trial: Temple Atrophy (2020)
The foundational clinical study for Renuva was a multicenter, open-label, IRB-approved pilot trial published in the Journal of Cosmetic Dermatology by Gold, Kinney, Kaminer, Rohrich, and D'Amico. Ten subjects (nine female, one male, aged 47–69) with bilateral temple atrophy received Renuva injections of less than 3 mL per temple.
Key findings over 24 weeks of follow-up:
- Volume retention: Mean temple fullness increased from 0 (baseline) to 2.8 immediately post-treatment on a 0–4 scale. Fullness varied from 0.8 to 2.2 during weeks 1–12 (reflecting the initial remodeling phase), then increased to 2.7–3.0 at weeks 16–24 — approximately 75% improvement over baseline.
- Tissue remodeling confirmed: Biopsy specimens demonstrated native tissue incorporation, neovascularization, and adipogenesis at the injection site.
- Skin quality improvement: Skin tone, smoothness, texture, and overall appearance improved in the treated area.
- Safety: Adverse events were minimal and self-resolving.
- Satisfaction: 71% of subjects reported being "satisfied" to "very satisfied" with results (Gold et al., 2020).
Real-World Case Series (2024)
A 2024 publication in the Journal of Cosmetic Dermatology presented seven real-world cases from nine expert cosmetic physicians across the United States. The cases demonstrated Renuva use for volume restoration in the face, hands, and body. The expert panel concluded that Renuva is "an easy-to-use, effective, and safe alternative to traditional fillers and fat grafting" (Gold et al., 2024).
Systematic Review (2025)
Morel et al. conducted a systematic review published in Plastic and Reconstructive Surgery (2025), synthesizing all available evidence on allograft adipose matrix. From 352 identified studies, 10 human studies (93 patients) and 9 animal studies met inclusion criteria. Key findings:
- Indications covered: Foot and dorsal hand rejuvenation, abdominal and buttocks contouring, temple atrophy, breast and genitalia augmentation, pressure ulcers, and facial rejuvenation
- Volume retention: Retention rates varied widely, ranging from 21.5% to 100% across studies
- Complications: The most common adverse events were erythema, swelling, injection site pain, and burning — all self-resolving
- Patient satisfaction: Ranged from 72.9% to 100%
- Histological findings: Consistent evidence of adipogenesis and neovascularization
- Animal studies: Suggested potential enhancements through combination therapies, including AAM with autologous fat, platelet-rich plasma, or synthetic scaffolds (Morel et al., 2025)
Vocal Fold Augmentation (2025)
A prospective clinical trial by Santa Maria et al. evaluated Renuva as an injection material for vocal fold augmentation in 21 patients with unilateral vocal fold paralysis. At 3-month follow-up, 81.3% of cases showed voice improvement by blinded assessment, with significant reductions in voice handicap scores (VHI-10 reduction of 11.3, p=0.02). No adverse reactions were reported. This study extends the potential applications of Renuva beyond aesthetic indications (Santa Maria et al., 2025).
Preclinical Evidence: Radiation-Induced Fibrosis
Adem et al. (Stanford University) demonstrated in a 2022 animal study that Renuva could alleviate radiation-induced skin fibrosis. In a murine model, DAM injection promoted adipogenesis and reduced fibrotic tissue in irradiated areas, suggesting a regenerative role beyond simple volume restoration (Adem et al., 2022).
Evidence Limitations
It is important to contextualize this evidence accurately:
- No large-scale randomized controlled trials have been completed
- Total patient numbers across all human studies remain under 100
- Most studies have follow-up periods of 6 months or less
- Volume retention rates vary significantly (21.5–100%), suggesting inconsistency that needs further investigation
- Many published studies involve investigators with industry relationships
- Long-term durability data (beyond 1 year) is limited
- Head-to-head comparisons with standard fillers or fat grafting are lacking
The systematic review authors explicitly note that "further research is needed to optimize decellularization protocols, improve bioactivity and tissue incorporation" and call for "larger, long-term clinical studies" (Morel et al., 2025).
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing and Procedure
The information below is for educational reference only. Renuva dosing, injection depth, and volume decisions require clinical training and assessment of individual anatomy. Improper technique can lead to complications including nodule formation or asymmetry.
Product Preparation
Renuva is supplied as a sterile, room-temperature-stored allograft that does not require reconstitution or thawing. The matrix is delivered pre-loaded or can be transferred to syringes for injection. Its shelf life is approximately 5 years at room temperature, making it a true "off-the-shelf" product — one of its key advantages over autologous fat grafting, which requires same-day harvest and processing.
Injection Technique
Renuva can be injected using standard needles (18–21 gauge) or blunt-tipped cannulas, depending on the treatment area and provider preference. Key procedural considerations:
- Anesthesia: Local anesthesia (lidocaine with or without epinephrine) is administered at the injection site. For larger body areas, tumescent anesthesia or nerve blocks may be used.
- Injection depth: The matrix is placed in the subcutaneous fat layer — the same tissue plane where native adipose tissue resides. This is critical for optimal cell recruitment and adipogenesis.
- Distribution: The matrix should be distributed evenly throughout the treatment area using a fanning or threading technique to maximize scaffold-tissue contact and promote uniform tissue regeneration.
- Overcorrection: Some providers recommend mild overcorrection (10–20%) to account for the initial volume dip during the remodeling phase before new adipocytes mature.
Volume Guidelines by Treatment Area
| Treatment Area | Typical Volume | Notes |
|---|---|---|
| Temples | 1–3 mL per side | Pilot study used <3 mL bilaterally with 75% improvement at 24 weeks |
| Facial volume (cheeks, nasolabial) | 2–6 mL total | Subcutaneous placement; may combine with HA filler for immediate result |
| Dorsal hands | 2–4 mL per hand | Addresses tendon visibility and skin thinning from fat and collagen loss |
| Feet (fat pad atrophy) | 3–6 mL per foot | Ball of foot or heel pad; functional and aesthetic indication |
| Breast (minor augmentation/asymmetry) | 10–50 mL per breast | Typically used for small corrections or reconstruction, not primary augmentation |
| Buttocks contouring | 20–60+ mL | Targeted correction; not a substitute for large-volume fat transfer (BBL) |
| Abdominal contour irregularities | 5–30 mL | Post-liposuction defects or soft tissue irregularities |
Sources: Gold et al., 2020 — Pilot study: temporal fossa rejuvenation (Aesthetic Surgery Journal) · Gold et al., 2024 — Real-world volume and outcomes data (Plastic and Reconstructive Surgery) · MTF Biologics — Product specifications and handling guidelines
Results Timeline
| Timepoint | What to Expect |
|---|---|
| Immediately | Volume from the injected matrix is visible. Some swelling from the procedure itself. The appearance at this stage reflects matrix volume, not new tissue. |
| Days 1–7 | Swelling peaks and begins resolving. Bruising possible, especially in vascular areas. Mild tenderness at injection sites. |
| Weeks 2–8 | The "dip phase." Initial volume decreases as the matrix is remodeled. This is normal and expected — the scaffold is being processed and repopulated with host cells. Patients should be counseled about this phase before treatment. |
| Weeks 8–16 | New adipocytes mature and accumulate lipid. Volume gradually returns and may exceed the dip phase nadir as neoadipogenesis progresses. |
| Months 4–6 | Final results become apparent. Tissue remodeling nears completion. Volume stabilizes as mature fat tissue is established. |
| Months 6+ | Stable, living fat tissue. Volume behaves like native fat — responsive to weight changes. Touch-up treatments can be performed if additional volume is desired. |
Sources: Gold et al., 2020 — 24-week temporal fossa results timeline · Gold et al., 2024 — Multi-site outcomes and remodeling timeline
Post-Procedure Care
- Avoid strenuous exercise for 48–72 hours
- Apply cold compresses for swelling as needed
- Avoid pressure or massage on treated areas for 1–2 weeks
- Follow-up assessment is typically scheduled at 4–6 weeks and again at 3–6 months to evaluate tissue remodeling
- Additional treatment sessions may be planned after initial results are assessed
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Safety
Common Side Effects
| Side Effect | Frequency | Duration | Notes |
|---|---|---|---|
| Swelling | Common | 3–14 days | Expected tissue response to injection. More pronounced in facial areas. |
| Erythema (redness) | Common | 1–7 days | At and around injection sites. Generally mild. |
| Injection site pain | Common | 1–5 days | Related to the injection procedure itself rather than the product. |
| Burning sensation | Occasional | Hours to days | Reported in some studies; self-resolving. |
| Bruising | Occasional | 5–14 days | Related to injection technique and tissue vascularity. |
| Firmness/nodularity | Uncommon | Weeks to months | May occur during the remodeling phase; typically resolves as tissue matures. |
Theoretical and Allograft-Specific Risks
As a human tissue allograft, Renuva carries risks inherent to all tissue transplantation, though the extensive processing and screening substantially reduce these:
- Disease transmission: Donor tissue is screened per FDA and AATB standards for communicable diseases (HIV, hepatitis B/C, syphilis, and others). The decellularization process removes cellular material, further reducing this already low risk. No cases of disease transmission have been reported with Renuva.
- Immune reaction: The decellularization process removes the cellular antigens that trigger immune rejection. The remaining ECM proteins are highly conserved across individuals and are nonimmunogenic. Clinical studies report no immune-mediated adverse events.
- Inconsistent volume retention: The systematic review documented retention rates ranging from 21.5% to 100%. This variability likely reflects differences in injection technique, treatment area, patient biology, and assessment methods — but it indicates that results are not uniformly predictable (Morel et al., 2025).
- Renuva is not reversible like HA fillers. Once injected, the matrix cannot be dissolved with hyaluronidase. If overcorrection occurs, surgical excision may be required.
- Long-term safety data beyond 1 year is limited. The total number of studied patients across all published literature is under 100.
- Renuva is not FDA-approved as a drug or device. It is regulated as a human tissue product (HCT/P). This regulatory pathway does not require the same premarket clinical trials as drugs or Class III medical devices.
- The product should be administered only by licensed healthcare providers experienced in soft tissue injection techniques.
Contraindications
- Active infection at the planned injection site
- Known allergy to any component of the processing solution
- Patients who are not candidates for allograft tissue transplantation
- Pregnancy and breastfeeding (not studied)
- Autoimmune conditions affecting connective tissue (relative contraindication — insufficient data)
Regulatory Framework
Renuva is regulated by the FDA as a human cells, tissues, and cellular and tissue-based product (HCT/P) under 21 CFR Part 1271. This regulatory framework applies to human tissues intended for transplantation — including bone, skin, tendons, and adipose tissue — that meet specific criteria for minimal manipulation and homologous use. Under Section 361 of the Public Health Service Act, qualifying HCT/Ps are subject to registration, listing, and good tissue practice requirements, but do not require premarket approval (PMA) or 510(k) clearance like medical devices.
This means Renuva has not undergone the same level of premarket clinical trial scrutiny as FDA-approved drugs or PMA-cleared devices (like HA fillers). The HCT/P pathway relies on tissue banking standards, donor screening, and processing controls rather than efficacy trials. This distinction is important for patients and providers to understand when evaluating the product (FDA: Tissue & Tissue Products).
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost
Estimated Cost by Treatment Area
| Treatment Area | Typical Volume | Estimated Cost |
|---|---|---|
| Temples | 2–6 mL total | $1,500–$3,000 |
| Cheeks / midface | 2–6 mL total | $1,500–$3,500 |
| Hands | 4–8 mL total | $2,000–$4,000 |
| Feet (fat pad restoration) | 6–12 mL total | $2,500–$5,000 |
| Body contouring (small area) | 10–30 mL | $3,000–$7,000 |
| Body contouring (large area) | 30–60+ mL | $5,000–$15,000+ |
What Affects Price
- Product volume: Renuva is sold by volume, and the per-mL cost reflects the complexity of tissue processing. Larger treatment areas require significantly more product.
- Geographic location: Pricing varies by market. Metropolitan areas with higher overhead tend to charge more.
- Provider expertise: Experienced physicians with specialized training in regenerative aesthetics may charge premium fees.
- Number of sessions: Some patients require a second treatment session (typically 3–6 months after the first) to achieve optimal volume, doubling the cost.
- Combination treatments: Some providers combine Renuva with HA filler (for immediate volume) or PRP (to potentially enhance adipogenesis), adding to total cost.
Insurance Coverage
Cosmetic uses of Renuva are not covered by health insurance. However, reconstructive applications — such as treatment of soft tissue defects from trauma, surgery, or radiation — may be eligible for insurance coverage under certain circumstances, as Renuva is classified as an allograft tissue product. Coverage is determined on a case-by-case basis by the patient's insurer.
Long-Term Value Proposition
The economic argument for Renuva rests on durability. If the regenerated tissue persists long-term (years rather than months), the per-year cost of volume maintenance may be lower than repeat synthetic filler treatments:
| Approach | Initial Cost | Retreatment Frequency | 5-Year Estimated Cost |
|---|---|---|---|
| HA filler (cheeks) | $1,600–$4,800 | Every 12–18 months | $5,000–$20,000 |
| Sculptra (cheeks) | $2,400–$4,800 | Every 24 months | $5,000–$12,000 |
| Renuva (cheeks) | $1,500–$3,500 | Potentially once (+ possible touch-up) | $1,500–$7,000 |
| Fat transfer (cheeks) | $3,000–$8,000 | Typically once | $3,000–$8,000 |
Caveat: The 5-year cost estimates for Renuva are projections based on the assumption of durable tissue regeneration. Long-term retention data beyond 6 months is limited, and some patients may require retreatment. These comparisons should be interpreted with appropriate caution.
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Comparisons
Renuva vs. Autologous Fat Transfer
| Factor | Renuva (AAM) | Autologous Fat Transfer |
|---|---|---|
| Source | Donated human tissue (allograft) | Patient's own fat (autologous) |
| Harvest required | No — off-the-shelf product | Yes — liposuction procedure required |
| Donor site morbidity | None | Bruising, swelling, pain at harvest site; contour irregularity possible |
| Anesthesia | Local anesthesia (in-office) | Local with sedation, or general anesthesia |
| Procedure time | 30–60 minutes | 1–3 hours (harvest + processing + injection) |
| Downtime | Minimal (1–3 days) | Moderate (1–2 weeks, including harvest site) |
| Volume retention | 21.5–100% (variable; limited data) | 20–80% (variable; more extensively studied) |
| Mechanism | Scaffold-mediated neoadipogenesis | Direct transplantation of living adipocytes |
| Immunogenic risk | Minimal (decellularized allograft) | None (autologous) |
| Available for lean patients | Yes — no harvest required | Limited by available fat deposits |
| Evidence base | Small pilot studies (n<100) | Extensive (decades of literature) |
| Cost | $1,500–$5,000+ per area | $3,000–$10,000+ (includes OR time) |
Renuva's primary advantage over fat transfer is convenience: no surgical harvest, no operating room, no general anesthesia, and minimal downtime. It is also available to lean patients with insufficient fat for harvest. Its primary disadvantage is a much thinner evidence base and less predictable volume retention.
Renuva vs. Hyaluronic Acid Fillers
| Factor | Renuva (AAM) | HA Fillers (Juvéderm, Restylane, etc.) |
|---|---|---|
| Material | Decellularized human adipose matrix | Cross-linked hyaluronic acid gel |
| Mechanism | Tissue regeneration (neoadipogenesis) | Mechanical volumization + hydration |
| Onset of results | Gradual (3–6 months for final result) | Immediate (final result at 2–4 weeks) |
| Duration | Potentially long-lasting (living tissue) | 6–24 months (product-dependent) |
| Reversibility | Not reversible | Fully reversible with hyaluronidase |
| FDA pathway | HCT/P (tissue regulation) | PMA (Class III medical device) |
| Evidence base | Limited (pilot studies, case series) | Extensive (large RCTs, decades of data) |
| Precision of correction | Less predictable (depends on tissue remodeling) | Highly predictable and titratable |
| Ideal use case | Broader volume restoration; tissue regeneration | Precise contouring; fine detail work |
Renuva vs. Biostimulators (Sculptra, Radiesse)
| Factor | Renuva (AAM) | Sculptra (PLLA) | Radiesse (CaHA) |
|---|---|---|---|
| Mechanism | ECM scaffold for adipogenesis | Collagen stimulation via foreign body response | Immediate fill + collagen stimulation |
| End product in tissue | Native fat cells | New collagen (type I) | New collagen (type I) |
| Onset | 3–6 months | 2–6 months (gradual collagen build) | Immediate + ongoing |
| Duration | Potentially years | Up to 25 months | 12–18 months |
| Reversibility | No | No | No (partially dilutable) |
| Sessions | 1–2 | 2–3 (spaced 4–6 weeks) | 1–2 |
| Material origin | Human tissue | Synthetic (poly-L-lactic acid) | Synthetic (calcium hydroxylapatite) |
When Renuva May Be Preferred
- Patients seeking long-term volume restoration without repeat filler treatments
- Lean patients who lack sufficient donor fat for autologous fat transfer
- Patients who want to avoid the surgical component of fat grafting (liposuction, OR time, general anesthesia)
- Treatment areas where native fat tissue is the ideal replacement (foot pads, hands, post-surgical defects)
- Patients with radiation-induced soft tissue damage or atrophy
- Those who prefer a human tissue-based product over synthetic materials
When Renuva May Not Be Ideal
- Patients who need immediate, precise, predictable volume correction (HA fillers offer more control)
- Patients who value reversibility as a safety net (HA fillers can be dissolved)
- Fine-detail work (lip borders, tear troughs, individual wrinkles) — HA fillers remain the gold standard
- Patients requiring extensive evidence before treatment (the AAM evidence base is still maturing)
- Large-volume body augmentation where fat transfer provides proven, cost-effective results
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Question: Is Renuva FDA-approved?
Answer: Renuva is not "FDA-approved" in the way that drugs or medical devices are approved. It is regulated by the FDA as a human tissue product (HCT/P) under 21 CFR Part 1271, Section 361 of the Public Health Service Act. This means it is subject to tissue banking regulations, donor screening requirements, and good tissue practice standards — but it does not undergo the premarket approval (PMA) process or 510(k) clearance pathway required for medical devices like HA fillers. This distinction matters: HCT/P regulation focuses on tissue safety (donor screening, processing standards), not on clinical efficacy demonstration through controlled trials.
Myth: Renuva is just another dermal filler.
Answer: Renuva is mechanistically distinct from dermal fillers. Dermal fillers (HA, CaHA, PLLA) are synthetic or semi-synthetic materials that physically occupy space or stimulate collagen production. Renuva is a decellularized human tissue scaffold that promotes the body's generation of new fat cells — the end result is living, native adipose tissue, not a foreign material sitting in the skin. The clinical implications are different: slower onset, potentially longer duration, no reversibility, and the regenerated tissue responds to physiological changes like weight fluctuation.
Question: How long do Renuva results last?
Answer: This is currently the most important unanswered question about Renuva. Because the mechanism produces new living fat tissue, the results are theoretically permanent in the sense that regenerated fat persists as a living tissue depot. However, published clinical data only extends to about 24 weeks (6 months) of follow-up, and the systematic review documents volume retention rates ranging from 21.5% to 100% — a wide range suggesting inconsistency. Longer-term data (1+ years, 5+ years) is needed before making definitive claims about permanence (Morel et al., 2025).
Question: Can Renuva be dissolved if I don't like the result?
Answer: No. Unlike hyaluronic acid fillers, which can be dissolved with hyaluronidase injection within hours, Renuva cannot be reversed with an enzyme. Once injected, the matrix integrates with tissue and is replaced by the body's own fat cells. If overcorrection or undesirable results occur, the options are limited to waiting (the volume may partially decrease during remodeling) or, in significant cases, surgical excision. This irreversibility is an important consideration when choosing between Renuva and HA fillers.
Myth: Using donated human tissue means there's a significant risk of disease transmission.
Answer: The risk of disease transmission with processed human tissue allografts is extremely low. Renuva donors are screened per FDA and AATB standards for communicable diseases. The decellularization process removes all living cells and blood components, further reducing any residual risk. The same tissue processing and safety standards apply to widely used allografts in orthopedic surgery (bone grafts, tendon allografts), dermal matrices used in reconstructive surgery, and other transplantation products. No cases of disease transmission have been reported with Renuva in published literature.
Question: Can Renuva be combined with other treatments?
Answer: Yes, combination approaches are emerging in clinical practice. Some providers inject HA filler at the same session as Renuva to provide immediate visible volume while the adipose matrix undergoes its weeks-to-months remodeling process. Others combine Renuva with platelet-rich plasma (PRP), hypothesizing that the concentrated growth factors in PRP may enhance adipogenesis within the scaffold. Animal studies have suggested benefits from combining AAM with autologous fat or PRP, but clinical data on combination protocols in humans remains limited (Morel et al., 2025).
Question: Who should perform Renuva injections?
Answer: Renuva should be administered by licensed healthcare providers experienced in soft tissue injection and familiar with facial and body anatomy. Board-certified dermatologists, plastic surgeons, facial plastic surgeons, and other specialists with demonstrated injection competence are the most qualified providers. Because Renuva is irreversible and involves allograft tissue, the stakes of improper placement are higher than with reversible HA fillers.
Question: Does Renuva work for everyone?
Answer: The wide range in reported volume retention (21.5–100%) suggests that individual outcomes vary considerably. Factors that likely influence results include local tissue vascularity, the patient's regenerative capacity (which may decline with age), injection technique, volume and distribution of the injected matrix, and the treatment area. Not enough data exists to reliably predict which patients will have excellent versus suboptimal results. Setting realistic expectations and discussing this variability with patients is essential.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Sources & Further Reading
Clinical Studies
- Gold MH, Kinney BM, Kaminer MS, Rohrich RJ, D'Amico RA (2020) — "A multi-center, open-label, pilot study of allograft adipose matrix for the correction of atrophic temples" — Journal of Cosmetic Dermatology, 19(5):1044-1056
- Gold M, Biesman B, Cohen J, Day D, Goldberg D, et al. (2024) — "Real-World Clinical Experience With an Allograft Adipose Matrix for Replacing Volume Loss in Face, Hands, and Body" — Journal of Cosmetic Dermatology, 23 Suppl 4:1-9
- Santa Maria C, Shuman EA, Bensoussan YE, et al. (2025) — "Prospective Short-Term Outcomes of Allograft Adipose Matrix (AAM) for Vocal Fold Augmentation" — Laryngoscope (online ahead of print)
Systematic Review
Preclinical / Basic Science
Regulatory
- 21 CFR Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based Products (FDA regulation)
- FDA: Tissue & Tissue Products — Regulatory Framework
- MTF Biologics — Manufacturer Website
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.